๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

A within-subject comparison of 6-[18F]Fluoro-m-Tyrosine (FMT) and 6-[18F]Fluoro-l-DOPA (FDOPA) in Parkinson disease (PD)

โœ Scribed by Catherine L. Gallagher; James Holden; Brad Christian; Sandra Harding; Robert J. Nickles; Sterling Johnson

Book ID
119331313
Publisher
Elsevier Science
Year
2010
Tongue
English
Weight
119 KB
Volume
52
Category
Article
ISSN
1053-8119

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

A within-subject comparison of 6-[18F]fl
A within-subject comparison of 6-[18F]fluoro-m-tyrosine and 6-[18F]fluoro-L-dopa in Parkinson's disease
โœ Catherine L. Gallagher; Bradley T. Christian; James E. Holden; Onofre T. Dejesus ๐Ÿ“‚ Article ๐Ÿ“… 2011 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 268 KB

## Abstract Progression of Parkinson's disease symptoms is imperfectly correlated with positron emission tomography biomarkers for dopamine biosynthetic pathways. The radiopharmaceutical 6โ€[^18^F]fluoroโ€mโ€tyrosine is not a substrate for catecholโ€__O__โ€methyltransferase and therefore has a more favo

Rate of progression in Parkinson's disea
Rate of progression in Parkinson's disease: A 6-[18F]fluoro-L-dopa PET study
โœ Elina Nurmi; Hanna M. Ruottinen; Jรถrgen Bergman; Merja Haaparanta; Olof Solin; P ๐Ÿ“‚ Article ๐Ÿ“… 2001 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 91 KB ๐Ÿ‘ 1 views

## Abstract The aim of this study was to investigate the rate of progression in Parkinson's disease (PD) with 6โ€[^18^F]fluoroโ€Lโ€dopa (FDOPA) positron emission tomography (PET). We investigated 21 patients with PD and eight healthy controls. Ten of the patients were de novo at the time of the first